Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 3/20 | 0.66 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.66 |
| ▸ | BCL6 | P41182 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183176 | 0.79 | KCNN3 (1.00) | KCNN3KCNN2BCL6HTTMAPT | |
| SCHEMBL30421528 | 0.79 | KCNN3 (1.00) | KCNN3KCNN2BCL6HTTMAPT | |
| SCHEMBL3238040 | 0.78 | KCNN3 (0.66) | KCNN3KCNN2BCL6HTTMAPT | |
| SCHEMBL183291 | 0.77 | CDK1 (0.51) | KCNN3KCNN2HTTMAPTCYP3A4 | |
| SCHEMBL183256 | 0.74 | KCNN3 (0.76) | KCNN3KCNN2BCL6HTTMAPT | |
| SCHEMBL21357700 | 0.74 | KCNN2 (0.59) | KCNN3KCNN2HTTMAPTNPC1 | |
| SCHEMBL183032 | 0.72 | KCNN3 (0.86) | KCNN3KCNN2BCL6HTTMAPT | |
| SCHEMBL2521840 | 0.70 | KCNN2 (0.55) | KCNN3KCNN2BCL6HTTMAPT | |
| SCHEMBL183487 | 0.70 | KCNN3 (0.79) | KCNN3KCNN2BCL6HTTMAPT | |
| SCHEMBL182996 | 0.70 | KCNN3 (0.80) | KCNN3KCNN2BCL6HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | claimed |
| EP-2402341-A2 | Purinyl derivatives and their use as potassium channel modulators | NeuroSearch A/S (DK) | 2012-01-04 | — | — | EP | claimed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | claimed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20130109704-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2013-05-02 | — | — | US | disclosed |
| US-8362024-B2 | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-8362024-B2 | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-8362024-B2 | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| EP-2402341-A2 | Purinyl derivatives and their use as potassium channel modulators | NeuroSearch A/S (DK) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402341-A2 | Purinyl derivatives and their use as potassium channel modulators | NeuroSearch A/S (DK) | 2012-01-04 | — | — | EP | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| WO-2008116909-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109704-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KCNN3 15/4885KCNN2 5/4885BCL6 4271/4885 |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | KCNN3 15/4885KCNN2 5/4885BCL6 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.